Follicular lymphoma group N = 17 | Mantle cell lymphoma group N = 29 | |
---|---|---|
Sex (F/M) | 7 (41.2%) / 10 (58.8%) | 6 (20.7%) / 23 (79. 3%) |
Age at diagnosis in years, median FL grade I/II IIIa Pleomorphic/blastoid MCL | 46 (range 29–62) 13 (76.5%) 4 (23.5%) / | 54 (range 38–65) / 10 (34.5%) |
Distribution according to FLIPI or MIPI low risk/intermediate/high risk HDT/ASCT After first line treatment* After second line treatment or later according to national guidelines; CR = complete remission; F = female; FL = follicular lymphoma; FLIPI = follicular lymphoma international prognostic index; HDT/ASCT = high dose treatment/autologous stem cell transplantation; M = male; MCL = mantle cell lymphoma; MIPI = international prognostic index for mantle cell lymphoma; N = number; PR = partial remission | 4 (23.5%) / 9 (52.9%) / 4 (23.5%) 3 (17.6%) 14 (82.4%) | 24 (82.8%) / 4 (13.8%) / 1 (3.4%) 24 (82.7%) 5 (17.2%) |
Disease status prior HDT/ASCT CR PR Documented rituximab treatment before HDT/ ASCT | 5 (29.4%) 12 (70.6%) 17 (100%) | 13 (44.8%) 16 (55.2%) 29 (100%) |